ArticleDermatology reports2025
Psoriasiform rash possibly induced by oral propranolol in a 12-month-old girl with infantile hemangioma: a case report and literature review.
Article in Dermatology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infantile hemangiomas are the most common soft-tissue tumors in children, with propranolol, a non-cardioselective β-blocker, considered the first-line treatment for complicated cases. β-blockers have been reported to be the most common causative agents for drug-induced psoriasis in adults. In the pediatric population, only one previous case has been reported. We report the case of a 12-month-old girl who developed a psoriasiform rash after starting oral propranolol for infantile hemangiomas on the scalp. The patient had no personal or family history of psoriasis. The rash appeared one week post-initiation of propranolol, presenting as well-defined erythematous, scaly plaques over the body, including the scalp. Infectious causes were excluded, and the rash was diagnosed as a psoriasiform rash, possibly induced by oral propranolol. The patient was switched to atenolol, which resulted in improvement of the hemangioma and complete resolution of the skin lesions. This case highlights the rare but significant risk of psoriasiform eruptions associated with β-blocker therapy in infants, emphasizing the need for careful recognition and monitoring of this potential adverse effect in pediatric patients treated for infantile hemangiomas.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.